HHS halts Eli Lilly’s single-drug COVID antibody treatment in U.S.; dual-drug alternative remains in...
By
Alicia Lasek
Mar 26, 2021
U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...
Gout guidance highlights treat-to-target drug therapy
By
Alicia Lasek
May 12, 2020
Experts strongly recommend moving away from a fixed-dose approach to urate lowering therapy in updated guidelines for 2020.
Clinical briefs for Wednesday, Dec. 1
By
Alicia Lasek
Dec 01, 2021
Regeneron’s COVID-19 antibody drug may be less effective against omicron, drugmaker says … Pandemic taking toll on healthcare workers’ sleep patterns … Ambulance staffing shortage frustrating nursing...
Feds halt an Eli Lilly antibody therapy in 3 states due to variant fears, while boosting the treatment...
By
Alicia Lasek
Mar 19, 2021
A COVID-19 variant circulating widely in California, Arizona and Nevada has rendered bamlanivimab alone ineffective, an FDA official reports. But Lilly says an approved alternative treatment “maintains...
Amyloid-busting drug for early Alzheimer’s fails to stop cognitive decline, long-term study concludes
By
Alicia Lasek (f3)
Jun 21, 2022
The failure of a more-than-decade-long trial in patients with early-onset Alzheimer’s deals yet another blow to a key treatment theory, observers say.
Alzheimer’s discoveries show new promise for drug development, expert says
By
Alicia Lasek
Jul 20, 2020
The discovery of new biomarkers — along with a focus on repurposed drugs — are optimistic signs for Alzheimer’s research, according to a five-year analysis.
High amyloid levels linked to early-stage Alzheimer’s
By
Alicia Lasek
Apr 06, 2020
Screening data from an Alzheimer’s drug trial suggests that higher brain amyloid levels exist well before clinical symptoms appear.
ADHD linked to Alzheimer’s disease across generations, scientists say
By
Alicia Lasek
Sep 14, 2021
Parents of children diagnosed with attention deficit hyperactivity disorder are more likely to receive a diagnosis of Alzheimer’s than their peers whose children do not have the condition, investigators...
Alzheimer’s origin story is about metabolism and lifestyle, scientists contend
By
Alicia Lasek
Apr 02, 2021
Alzheimer’s Disease is increasingly being referred to as insulin resistance of the brain, or Type 3 diabetes, a research team says.
Immune system boost is reason not to skip second COVID-19 shot, study finds
By
Liza Berger
Jul 20, 2021
The second dose of a COVID-19 vaccine offers a serious boost to a part of the immune system that provides broad antiviral protection, according to a Stanford University School of Medicine study. This finding...